Figure 3 | Scientific Reports

Figure 3

From: Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway

Figure 3

Monensin acts synergistically with gemcitabine or erlotinib on inhibiting cell proliferation of human pancreatic cancer cells. (A,B) Crystal violet assay for drug combinations. Panc-1 (A) and MiaPaCa-2 (B) cells were treated with monensin/gemcitabine combination (a) or monensin/erlotinib combination (b) at the indicated concentrations. At 72 h post treatment, cells were fixed and stained with crystal violet. Representative results are shown. (C) WST-1 assay for drug combinations and Chou-Talalay drug combination index analysis. Panc-1 (a,b) and MiaPaCa-2 (c,d) cells were treated with monensin/gemcitabine combination or monensin/erlotinib combination at indicated concentrations (a,c). At 48 h post treatment, WST-1 reagent was added to each well and incubated for 30 min. WST-1 activities were measured and graphed. The WST-1 assay data were further calculated for the combination index (CI) using the Chou-Talalay method (b,d). CI < 1, synergistic effect; CI = 1, additive effect; and CI > 1, antagonistic effect.

Back to article page